Overview

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Status:
Recruiting

Trial end date:
2026-06-26

Target enrollment:

Participant gender:

Summary

This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Daiichi Sankyo, Inc.

Treatments:

Cyclophosphamide
Doxorubicin
Paclitaxel
Pertuzumab
Trastuzumab